REAL WORLD USE AND OUTCOMES OF OLAPARIB IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER: A RETROSPECTIVE STUDY FROM ITALIAN ADMINISTRATIVE DATABASES
Author(s)
Silvia Calabria, PharmD1, Chiara Veronesi, MSc1, Paolo Luraghi, PhD2, Giovanna Neri, MSc2, Serena Losi, MSc2, Daniela Castelletti, PhD2, Micol Macellari, MSc2, Luca Degli Esposti, PhD1.
1CliCon S.r.l. Società Benefit, Bologna, Italy, 2AstraZeneca S.p.A., Milan, Italy.
1CliCon S.r.l. Società Benefit, Bologna, Italy, 2AstraZeneca S.p.A., Milan, Italy.
OBJECTIVES: Olaparib is a potent PARP inhibitor approved and reimbursed by the Italian Medicines Agency as monotherapy since March 2022 or combination therapy since February 2025 for with metastatic castration-resistant prostate cancer (mCRPC). This analysis aimed to describe olaparib utilization in adults with mCRPC in Italy.
METHODS: This retrospective observational analysis of Italian administrative databases covering approximately 6 million inhabitants identified adult male patients with ≥1 olaparib prescription (ATC-code L01XK01) from 01/03/2022 to 30/09/2025 (index date) and diagnosed with PC through in-hospital ICD-9-code 185 or ≥1 prescription of androgen deprivation therapy (ADT) (ATC-codes: G03HA01-L02AE01-L02AE02-L02AE03-L02AE04-L02BX01-L02BX02-L02BB01-L02BB02-L02BB03) before the index-date. Patients with pancreas cancer (ICD-9-code 157) were excluded. Patients were characterized at baseline. Olaparib utilization and overall survival (OS) were described during the available follow-up.
RESULTS: Patients with mCRPC treated with olaparib were 71, on average aged 72.5±9.1 years, and with a Charlson Comorbidity Index of 1.24±2.0. Most patients had hypertension (70.4%), dyslipidemia (50.7%), and diabetes (33.8%). Half of patients received olaparib as 2L after a new hormone therapy (NHT), and 35.2% as 3L (35.2%) after NHT and CHT. Olaparib discontinuation occurred in 60.3% patients, after a median time of 1.2 years, indicating sustained treatment benefit in routine clinical practice. All-cause mortality was observed in 35.1%, with a median time to death of 1.8 years from olaparib initiation.
CONCLUSIONS: In this real-world cohort of patients with mCRPC, olaparib showed meaningful and durable clinical benefit, as reflected by a median treatment duration of more than 1 year and favorable overall survival outcomes. Collectively, these findings support the effectiveness of olaparib in routine clinical practice, suggesting that an earlier treatment initiation after progression on NHT may help optimize treatment duration and survival outcomes.
METHODS: This retrospective observational analysis of Italian administrative databases covering approximately 6 million inhabitants identified adult male patients with ≥1 olaparib prescription (ATC-code L01XK01) from 01/03/2022 to 30/09/2025 (index date) and diagnosed with PC through in-hospital ICD-9-code 185 or ≥1 prescription of androgen deprivation therapy (ADT) (ATC-codes: G03HA01-L02AE01-L02AE02-L02AE03-L02AE04-L02BX01-L02BX02-L02BB01-L02BB02-L02BB03) before the index-date. Patients with pancreas cancer (ICD-9-code 157) were excluded. Patients were characterized at baseline. Olaparib utilization and overall survival (OS) were described during the available follow-up.
RESULTS: Patients with mCRPC treated with olaparib were 71, on average aged 72.5±9.1 years, and with a Charlson Comorbidity Index of 1.24±2.0. Most patients had hypertension (70.4%), dyslipidemia (50.7%), and diabetes (33.8%). Half of patients received olaparib as 2L after a new hormone therapy (NHT), and 35.2% as 3L (35.2%) after NHT and CHT. Olaparib discontinuation occurred in 60.3% patients, after a median time of 1.2 years, indicating sustained treatment benefit in routine clinical practice. All-cause mortality was observed in 35.1%, with a median time to death of 1.8 years from olaparib initiation.
CONCLUSIONS: In this real-world cohort of patients with mCRPC, olaparib showed meaningful and durable clinical benefit, as reflected by a median treatment duration of more than 1 year and favorable overall survival outcomes. Collectively, these findings support the effectiveness of olaparib in routine clinical practice, suggesting that an earlier treatment initiation after progression on NHT may help optimize treatment duration and survival outcomes.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
HSD14
Topic
Health Service Delivery & Process of Care
Disease
Oncology